Meczin 50 Tablet: Each tablet contains Meclizine Hydrochloride USP 50 mg.
Meclizine has antiemetic, anticholinergic and antihistaminic properties. It reduces the sensitivity of the labyrinthine apparatus. The action may be mediated through nerve pathways to the vomiting center (VC) from the chemoreceptor trigger zone (CTZ), peripheral nerve pathways, the VC, or other CNS centers. Meclizine has an onset of action of 30 to 60 minutes, depending on dosage; their duration of action is 12 to 24 hours.
Prevention and treatment of nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of the vestibular system (e.g. labyrinthitis and other vestibular disturbances).
DOSAGE AND ADMINISTRATION
Adult & children over 12 years of age:
- Nausea and vomiting: 25-50 mg once daily.
- Motion sickness: Take an initial dose of 25 to 50 mg, 1 hour prior to travel. May repeat dose every 24 hours for the duration of the journey. Children: Age 6-12 years, 12.5 mg once daily. Age 2-6 years, 6.25 mg once daily.
- Vertigo: 25 to 100 mg daily in divided doses.
- Radiotherapy induced nausea and vomiting: 50 mg two to twelve hours prior to radiotherapy.
- Emergency contraception: 25-50 mg, 1 hour before first ECP dose; repeat if needed in 24 hours.
Use in children: Clinical studies establishing safety and efficacy in children have not been done; therefore, its use should be determined by physician.
Use in elderly: There is no specific information available. However older people may be especially sensitive to the anticholinergic effects of medicine.
Meczin (Meclizine) is contraindicated in patients who are hypersensitive to it.
Patients should be warned that Meczin (Meclizine) may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g. operating machinery, driving a motor vehicle). Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.
Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.
USE IN PREGNANCY AND LACTATION
Pregnancy: Category B. Large scale human studies have not demonstrated adverse fetal effects. It has been suggested that, based on available data, Meczin (Meclizine) presents the lowest risk of teratogenicity and is the drug of first choice in treating nausea and vomiting during pregnancy.
Lactation: Safety for use in the nursing mother has not been established.
Meclizine may increase the toxicity with CNS depressants, neuroleptics and anticholinergic. Alcohol, sedatives and tranquilizers can increase the drowsiness of the patient.
Symptoms: Extreme excitability, seizures, drowsiness and hallucinations.
Treatment: Appropriate supportive and symptomatic treatment. Consider dialysis.
Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.
Meczin 50 Tablet: Box containing 10 X 5 tablets in blister pack.